Deputy Director
National Institute on Drug Abuse, Maryland
Wilson M. Compton, M.D., M.P.E. is Deputy Director of the National Institute on Drug Abuse of the National Institutes of Health. Before joining NIDA in 2002, Dr. Compton was a tenured faculty member in the Department of Psychiatry and Director of the Master in Psychiatric Epidemiology Program at Washington University in Saint Louis as well as Medical Director of Addiction Services at the Barnes-Jewish Hospital. Dr. Compton received his undergraduate education from Amherst College. He attended medical school and completed residency training in psychiatry at Washington University in Saint Louis.
Over his career, Dr. Compton has achieved multiple scientific accomplishments. He has authored over 200 publications, including widely-cited papers on the U.S. opioid crisis., and has been an invited speaker at multiple high-impact venues. He was a member of DSM-5’s Revision Task Force and has led, for NIDA, development of the Population Assessment of Tobacco and Health Study (PATH), a longitudinal population study, jointly sponsored by NIDA and the U.S. Food and Drug Administration (FDA), with 45,971 baseline participants who provide survey responses and biological assessments to inform the development of tobacco regulations in the United States.
Dr. Compton is a member of numerous professional organizations, including the Alpha Omega Alpha medical education honor society. Dr. Compton is also the recipient of multiple awards, including the Senior Scholar Health Services Research Award from the American Psychiatric Association in 2008 and the Paul Hoch Award from the American Psychopathological Association in 2010. The FDA selected him to receive collaboration and cross-cutting awards in 2012, 2013 and 2017. In 2018, Dr. Compton received the James W. West award from the National Association of Addiction Treatment Providers. Dr. Compton also received the Health and Human Services Secretary’s Awards for Meritorious Service in 2013 and Distinguished Service in 2015, 2018 and 2019.
3M Companies (Ownership Interest includes stock, stock options, patent or other intellectual property)General Electric Co. (Ownership Interest includes stock, stock options, patent or other intellectual property)Pfizer, Inc. (Ownership Interest includes stock, stock options, patent or other intellectual property)
Saturday, April 2, 2022
11:30 AM – 12:30 PM ET
